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INTRODUCTION {#ner13172-sec-0005}
============

The outbreak of coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which originated in Wuhan, China ([1](#ner13172-bib-0001){ref-type="ref"}), has spread rapidly and was declared a global pandemic by the World Health Organization on March 11, 2020 ([2](#ner13172-bib-0002){ref-type="ref"}). The clinical spectrum of COVID‐19 broadly varies from asymptomatic to critical illness ([3](#ner13172-bib-0003){ref-type="ref"}). As of April 21, 2020, more than 2.5 million confirmed cases and more than 175,000 deaths had been reported across 185 countries/regions ([4](#ner13172-bib-0004){ref-type="ref"}). Patients who are most severely affected report moderate to severe respiratory symptoms ([5](#ner13172-bib-0005){ref-type="ref"}), develop pneumonia and/or acute respiratory distress syndrome (ARDS), and require intensive care and/or respiratory support ([3](#ner13172-bib-0003){ref-type="ref"}, [5](#ner13172-bib-0005){ref-type="ref"}, [6](#ner13172-bib-0006){ref-type="ref"}). An extreme immune reaction, often referred to as a *cytokine storm*, that results in elevated levels of inflammatory cytokines including interleukin (IL)‐6 appears to be linked to increased mortality from COVID‐19 ([7](#ner13172-bib-0007){ref-type="ref"}, [8](#ner13172-bib-0008){ref-type="ref"}, [9](#ner13172-bib-0009){ref-type="ref"}), and strategies to mitigate the cytokine storm are being considered at this time. Symptomatic control has been complicated by concerns about inadvertent viral spread associated with the use of nebulizers and steroids, both of which are mainstays of conventional treatment for bronchoconstriction.

Vagus nerve stimulation (VNS) has been shown to be a potent modulator of pathologic immune reactions, specifically suppressing inflammatory cytokine levels via activation of the cholinergic anti‐inflammatory pathway (CAP) ([10](#ner13172-bib-0010){ref-type="ref"}, [11](#ner13172-bib-0011){ref-type="ref"}, [12](#ner13172-bib-0012){ref-type="ref"}). Inflammatory cytokines have been modulated by VNS in a variety of acute and progressive inflammatory conditions ranging from septic shock ([13](#ner13172-bib-0013){ref-type="ref"}, [14](#ner13172-bib-0014){ref-type="ref"}) and asthma ([15](#ner13172-bib-0015){ref-type="ref"}) to stroke ([16](#ner13172-bib-0016){ref-type="ref"}) and rheumatoid arthritis ([17](#ner13172-bib-0017){ref-type="ref"}). In models of acute septic shock, VNS consistently demonstrated life‐saving potential by reducing the expression of inflammatory cytokines ([13](#ner13172-bib-0013){ref-type="ref"}).

Non‐invasive vagus nerve stimulation (nVNS; gammaCore™, electroCore, Inc.; Fig. [1](#ner13172-fig-0001){ref-type="fig"}) is a neuromodulatory therapy that is U.S. Food and Drug Administration approved for acute and preventive treatment of migraine and cluster headache. It is CE marked in the EU for the treatment and prevention of symptoms of reactive airway disease, which includes asthma, bronchoconstriction, exercise‐induced bronchospasm, and chronic obstructive pulmonary disease (COPD), as well as for a number of other conditions. Clinical data suggest that nVNS might provide benefits in patients who have respiratory symptoms that are sometimes associated with COVID‐19, such as acute bronchoconstriction due to asthma ([18](#ner13172-bib-0018){ref-type="ref"}) and respiratory distress associated with COPD ([19](#ner13172-bib-0019){ref-type="ref"}).

![Treatment with non‐invasive vagus nerve stimulation. \[Color figure can be viewed at <http://wileyonlinelibrary.com>\]](NER-9999-na-g001){#ner13172-fig-0001}

Mechanistic and clinical data also demonstrate the potential for nVNS to mitigate the elevated cytokine levels caused by the cytokine storm in patients with COVID‐19 ([20](#ner13172-bib-0020){ref-type="ref"}, [21](#ner13172-bib-0021){ref-type="ref"}). The excellent safety and tolerability profile of nVNS further strengthens the case for its study and use in patients with COVID‐19. We now share our early clinical observations from two patients treated with nVNS for the treatment of respiratory symptoms associated with COVID‐19.

MATERIALS AND METHODS {#ner13172-sec-0006}
=====================

Information was obtained via email correspondence and patient phone interviews. Informed consent was obtained for the publication of the patients\' case reports.

RESULTS {#ner13172-sec-0007}
=======

Case 1 {#ner13172-sec-0008}
------

On March 23, 2020, a 50‐year‐old man developed symptoms of severe body aches; painful, unrelenting cough; a tingling sensation along the midline of his chest; anosmia; ageusia; and dyspnea. He was admitted to New York‐Presbyterian Lawrence Hospital in Bronxville, New York, in the early morning of March 24. The patient\'s intercurrent medical conditions included type 2 diabetes mellitus, hypertension, sleep apnea, and seasonal allergies. He also had a history of hypercholesterolemia and ongoing use of a continuous positive airway pressure device for sleep apnea for 15 years. There was no history of smoking. Ongoing medications at hospital admission included ramipril (10 mg/d, for hypertension), metformin (2000 mg/d, for diabetes), glipizide (10 mg/d, for diabetes), and atorvastatin (40 mg/d for hypercholesterolemia). At that time, the patient was tachycardic and hypertensive, and his blood glucose level was elevated. He was afebrile; the highest recorded body temperature was 99.0 °F. Chest X‐ray, electrocardiogram, and laboratory results were normal, and myocardial infarction was ruled out. He was provided supplemental oxygen (2 L via nasal cannula) but reported that he repeatedly stopped using it, owing to nasal dryness and epistaxis. His oxygen saturation was monitored (lowest recorded measurement, 93%). He received oral oxycodone (5 mg)/acetaminophen (325 mg) every four hours for pain. For cough, he initially received dextromethorphan/guaifenesin/acetaminophen every four hours, which was subsequently replaced with hydrocodone bitartrate/homatropine methyl bromide (5 mL every six hours).

On March 25, nasopharyngeal swab testing confirmed the presence of SARS‐CoV‐2. All other viral swab cultures were negative. He was treated with oral hydroxychloroquine (600 mg), oral azithromycin (500 mg for one day followed by 250 mg/d for four days), and inhaled albuterol as needed. A nebulizer was not used owing to concerns about potentially aerosolizing SARS‐CoV‐2. He continued to have severe, unrelenting cough and body aches, but his dyspnea had subsided, except during coughing bouts. He was discharged from the hospital and returned home on March 26. At the time of discharge, his blood glucose level and blood pressure were within normal levels, and his heart rate, although still elevated, had decreased to \~90 beats/min. His main symptoms of cough and body aches were adequately controlled with medication.

The patient, a clinician who had familiarity with neuromodulation through his practice, began using nVNS to treat his respiratory symptoms and expedite recovery at home. His typical treatment regimen consisted of two consecutive 120‐second periods of stimulation (one on each side of the neck) administered approximately every three hours while awake. He reported using additional nVNS treatment (two stimulation episodes) as needed, approximately once per day. He discontinued use of both oxycodone/acetaminophen and hydrocodone bitartrate/homatropine methyl bromide on March 28, two days after hospital discharge. On April 2, with continued use of nVNS every three hours when awake, his main symptoms were fatigue and low appetite, and coughing bouts had become rare. At last communication on April 7, he reported that he continued to use nVNS three times per day.

Case 2 {#ner13172-sec-0009}
------

On March 15, 2020, a 49‐year‐old man, a PhD scientist, with a 40‐year history of asthma and no history of smoking experienced excessive fatigue. The following day, he developed symptoms of fever (highest recorded oral temperature, 100.6 °F), chills, cough, throat soreness, mental cloudiness, and chest tightness. He noted that his cough was usually dry, but was sometimes productive, and he periodically used airway clearance exercises, which he had previously used for his asthma. On March 18, he phoned his physician, who advised testing for COVID‐19. The test was performed via nasopharyngeal swab at Kaiser Permanente South Baltimore County Medical Center on March 19 and processed by Quest Diagnostics™. Test results, available on March 27, confirmed the presence of SARS‐CoV‐2.

At the time his COVID‐19 symptoms began, the patient was taking pantoprazole (80 mg/d) for gastroesophageal reflux disease, loratadine (20 m/d) for allergies, and montelukast (10 mg/d) for asthma. Previously, he had used nVNS, with or without inhaled levalbuterol to prevent wheezing related to his asthma, but he had not used either treatment during the preceding approximately six weeks.

On March 17, he began using nVNS therapy (one 120‐second period of stimulation on the right side of the neck, two to three times per day) for COVID‐19‐associated symptoms of dyspnea and chest pressure/tightness. nVNS use was reported to provide immediate and consistent symptom relief and an improvement in his ability to clear his lungs. By March 21, the patient\'s fever, body aches, and mental cloudiness had ceased. On March 22, his asthma symptoms worsened, and he resumed use of inhaled levalbuterol concomitantly with nVNS therapy, as needed. He was prescribed an antibiotic (azithromycin) and oral steroids on March 23 but indicated that he did not take the oral steroids as he continued to experience substantial relief from his respiratory symptoms with use of nVNS and levalbuterol. He was also worried about sustained shedding of the virus due to immunosuppression with the steroids ([22](#ner13172-bib-0022){ref-type="ref"}). As of April 2, his remaining symptom was a periodic, unproductive cough.

DISCUSSION {#ner13172-sec-0010}
==========

These cases highlight the potential utility of nVNS in COVID‐19 symptom management. In both cases, nVNS therapy rapidly provided clinically relevant benefits to the patients. In case 1, the patient used nVNS to aid in his recovery at home after hospital discharge. He was able to discontinue use of opioid and cough suppressant medications with nVNS use. In case 2, the patient experienced immediate (within five minutes of the stimulation) and reliable relief from chest tightness and dyspnea, as well as an improved ability to clear his lungs when he used nVNS to manage his symptoms at home. Avoidance of ventilator dependence in both cases and lack of hospitalization in case 2 cannot be causally attributed to nVNS, but it is reasonable to speculate that nVNS therapy may have been a supporting factor, via either bronchodilation or inhibition of cytokine release. In light of significant concerns about inadequate numbers of intensive care unit beds and ventilators amid the rapid spread of COVID‐19, it is imperative to consider all viable therapeutic options that could lead to symptomatic improvement and decrease the need for hospitalization and subsequent mechanical ventilation. The well‐established safety and tolerability of nVNS therapy make it a particularly attractive treatment modality that merits immediate study.

Information about the mechanisms and the clinical spectrum of COVID‐19 is developing rapidly. Data thus far suggest that the viral infection is capable of producing an extreme immune reaction in the host, often referred to as a *cytokine storm* ([8](#ner13172-bib-0008){ref-type="ref"}, [9](#ner13172-bib-0009){ref-type="ref"}). IL‐6, which is produced by activated leukocytes and acts on several cell and tissue types, is believed to be a key cytokine in COVID‐19; IL‐6 levels have been closely linked with disease severity and progression ([7](#ner13172-bib-0007){ref-type="ref"}, [8](#ner13172-bib-0008){ref-type="ref"}). Clinically, respiratory symptoms of COVID‐19 appear to stem from inflammatory‐induced lung injury ([8](#ner13172-bib-0008){ref-type="ref"}) and cause a decrease in oxygen saturation (≤93% in severe cases) ([5](#ner13172-bib-0005){ref-type="ref"}). This leads to rapid deterioration of respiratory function, which, if not mitigated, can result in ARDS, diffuse organ involvement, and, in many cases, death ([1](#ner13172-bib-0001){ref-type="ref"}, [23](#ner13172-bib-0023){ref-type="ref"}, [24](#ner13172-bib-0024){ref-type="ref"}). Therapies that mitigate or block the cytokine storm could potentially decrease the need for long‐term respiratory support and mechanical ventilation. Ultimately, this could lead to decreased mortality.

There are two presumed mechanisms by which VNS may help patients with respiratory distress due to COVID‐19. First, the smooth muscles found in the walls of bronchi and bronchioles regulate the flow of air into the lungs ([25](#ner13172-bib-0025){ref-type="ref"}). Under normal conditions, when greater volumes of air are required by the body, smooth muscle relaxes to dilate the bronchi and bronchioles ([26](#ner13172-bib-0026){ref-type="ref"}). When the inflammatory response is dysregulated, bronchoconstriction results, limiting the flow of air to and from the lungs. VNS may inhibit this airway constriction through a parasympathetic‐sympathetic reflex arc, whereby stimulation of an afferent vagal nerve causes an efferent sympathetically mediated release of catecholamines that results in smooth muscle relaxation ([27](#ner13172-bib-0027){ref-type="ref"}). This represents an additional benefit of VNS, considering the potential for viruses to induce asthmatic reactions ([28](#ner13172-bib-0028){ref-type="ref"}).

The potential for nVNS to decrease cough may be of particular benefit for patients with COVID‐19, as mitigating cough at any stage of the disease is likely to curb transmission. For patients with asthma caused by viruses such as COVID‐19 or other respiratory conditions, nebulizers are often prescribed acutely to deliver corticosteroids and/or other therapeutic agents. As illustrated in case 2, nVNS may represent an alternative therapy for airway reactivity. This could potentially decrease the use of both nebulizers and corticosteroids in patients with COVID‐19, which has been recommended by the World Health Organization owing to concerns about furthering the spread of SARS‐CoV‐2 ([29](#ner13172-bib-0029){ref-type="ref"}, [30](#ner13172-bib-0030){ref-type="ref"}). Animal and human models have demonstrated a catecholamine mechanism of action and clinical utility of VNS in the emergency department for patients with severe airway reactivity. Moreover, with growing concern that nebulizers or steroids could increase viral spread, it is desirable to attain symptomatic control without this risk.

Second, the CAP is believed to be the vagus nerve--based arm of the inflammatory reflex ([31](#ner13172-bib-0031){ref-type="ref"}). Evidence indicates that stimulation of the CAP leads to acetylcholine (ACh) binding to α‐7‐nicotinic ACh receptors (α7nAChRs), resulting in reduced production of the inflammatory cytokines tumor necrosis factor (TNF), IL‐1β, and IL‐6 ([31](#ner13172-bib-0031){ref-type="ref"}, [32](#ner13172-bib-0032){ref-type="ref"}, [33](#ner13172-bib-0033){ref-type="ref"}). The use of the CAP to regulate the inflammatory response has been investigated broadly using varying forms of VNS for more than 20 years ([10](#ner13172-bib-0010){ref-type="ref"}, [32](#ner13172-bib-0032){ref-type="ref"}). The use of nVNS to target neural pathways to treat inflammatory diseases represents the most recent exploration of this pathway.

Clinical studies that support the utility of nVNS to affect both of these mechanistic pathways are listed and summarized in Table [1](#ner13172-tbl-0001){ref-type="table"}. Preliminary evidence from multiple clinical trials suggests that nVNS could ease the breathing and confer symptomatic relief in patients with asthma or COPD ([18](#ner13172-bib-0018){ref-type="ref"}, [19](#ner13172-bib-0019){ref-type="ref"}, [34](#ner13172-bib-0034){ref-type="ref"}). Initial human clinical work was performed with a minimally invasive form of VNS delivered through a percutaneous electrode in severely compromised patients with asthma who had a forced expiratory volume in one second (FEV~1~) that was 25%‐75% of normal ([35](#ner13172-bib-0035){ref-type="ref"}). A continuous 60‐minute stimulation of the vagus nerve at 25 Hz provided a clinically meaningful improvement (versus historical controls) in FEV~1~ and the work of breathing. In the second study, subjects received discrete 2‐minute nVNS doses, and the change in FEV~1~ was measured 1, 5, and 90 minutes after stimulation ([25](#ner13172-bib-0025){ref-type="ref"}, [34](#ner13172-bib-0034){ref-type="ref"}). Improvements in FEV~1~ were noted in 19 of the 29 subjects (66%) at one minute, 18 subjects (62%) at five minutes, and 25 subjects (86%) at 90 minutes. Improvements in the work of breathing, peak expiratory flow, and visual analog scale of dyspnea scores were also reported.

###### 

Summary of nVNS Trials Relevant to COVID‐19.

+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+-----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Study                                                                                                                                               | Design                                                   | *N* | Findings relevant to COVID‐19                                                                                                                                            |
+:====================================================================================================================================================+:=========================================================+:====+:=========================================================================================================================================================================+
| *Respiratory clinical trials*                                                                                                                       |                                                          |     |                                                                                                                                                                          |
+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+-----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| nVNS for the treatment of acute asthma exacerbations ([18](#ner13172-bib-0018){ref-type="ref"})                                                     | Prospective, multicenter, open‐label study               | 4   | Ninety minutes after acute nVNS treatment, FEV~1~ improved from baseline by a mean of 73%, and mean VAS dyspnea score decreased from 8 (at baseline) to 1                |
+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+-----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| nVNS for the relief of acute bronchoconstriction due to asthma ([25](#ner13172-bib-0025){ref-type="ref"}, [34](#ner13172-bib-0034){ref-type="ref"}) | Prospective, multicenter, open‐label study               | 30  | Ninety minutes after acute nVNS treatment, 93% of patients reported improvement in VAS dyspnea score, and 86% had improvements in FEV~1~                                 |
+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+-----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| nVNS for the prophylactic treatment of COPD ([19](#ner13172-bib-0019){ref-type="ref"})                                                              | Prospective, single‐center, randomized, controlled trial | 54  | After 8 weeks of daily treatment, the nVNS group had a significant increase from baseline in distance walked (9.9‐m greater improvement than the sham group) on the 6MWT |
+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+-----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| *Inflammatory clinical and mechanistic trials*                                                                                                      |                                                          |     |                                                                                                                                                                          |
+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+-----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| nVNS decreases whole blood culture--derived cytokines and chemokines ([20](#ner13172-bib-0020){ref-type="ref"})                                     | Randomized, blinded, pilot trial in healthy controls     | 20  | Twenty‐four hours after treatment, the nVNS group had a greater (vs the sham group) percentage decrease in levels of IL‐1β, TNF, IL‐6, IL‐8, MIP‐1α, and MCP‐1           |
+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+-----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Effects of nVNS on fatigue and immune responses in patients with primary Sjögren\'s syndrome ([21](#ner13172-bib-0021){ref-type="ref"})             | Prospective, single‐center, open‐label study             | 15  | Ninety minutes after nVNS, levels of MIP‐1α, IL‐1β, TNF‐α, IL‐6, and IP‐10 were significantly reduced on days 0, 7, and 28 of the study                                  |
|                                                                                                                                                     |                                                          |     |                                                                                                                                                                          |
|                                                                                                                                                     |                                                          |     | Twelve participants had an improvement in their fatigue scores, seven of whom had a ≥30% reduction in fatigue within 28 days                                             |
+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------+-----+--------------------------------------------------------------------------------------------------------------------------------------------------------------------------+

6MWT, 6‐minute walk test; COPD, chronic obstructive pulmonary disease; COVID‐19, coronavirus disease 2019; FEV~1~, forced expiratory volume in one second; IL, interleukin; IP, interferon γ‐induced protein; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; nVNS, non‐invasive vagus nerve stimulation; TNF, tumor necrosis factor; VAS, visual analog scale.

Multiple studies also demonstrate the ability of nVNS to decrease the level of inflammatory cytokines. The first, conducted in healthy individuals, showed a greater percentage reduction in IL‐1β, TNF, IL‐6, IL‐8, macrophage inflammatory protein (MIP)‐1α, and monocyte chemoattractant protein (MCP)‐1 levels in nVNS‐treated subjects than in sham‐treated control subjects ([20](#ner13172-bib-0020){ref-type="ref"}). In patients with Sjögren\'s syndrome (an inflammatory immune‐mediated condition), levels of MIP‐1α, IL‐1β, TNF‐α, IL‐6, and interferon γ--induced protein (IP)‐10 were significantly reduced 90 minutes after stimulation as well as at days 7 and 28 of the study ([21](#ner13172-bib-0021){ref-type="ref"}). Recently, nVNS was found to downregulate levels of several inflammatory cytokines, including IL‐6, in patients with post‐traumatic stress disorder (D. Bremner, MD, personal communication, April 14, 2020). In these studies, nVNS was used on a consistent basis, with additional acute use as needed for symptom control in some cases. This dosing regimen provides needed flexibility for patients whose respiratory symptoms may vary substantially over the course of their illness.

There is a strong scientific and clinical foundation for the hypothesis that nVNS can improve disease outcomes in patients with COVID‐19. Previous findings suggest that the clinical benefits from VNS and nVNS are driven by mechanisms of action relevant to COVID‐19. The robust established safety and tolerability profile of nVNS strengthens the case for the additional investigation and use of nVNS to fight the COVID‐19 pandemic. An Emergency Use Authorization application was recently submitted to the U.S. Food and Drug Administration to facilitate use and further study of nVNS during the COVID‐19 pandemic ([36](#ner13172-bib-0036){ref-type="ref"}). Randomized controlled trials are being initiated at multiple sites in the United States and Europe.
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